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ABSTRACT
Background: CD300LG rs72836561 (c.313C>T, p.
Arg82Cys) has in genetic-epidemiological studies been
associated with the lipoprotein abnormalities of the
metabolic syndrome. CD300LG belongs to the CD300-
family of membrane-bound molecules which have the
ability to recognize and interact with extracellular
lipids. We tested whether this specific polymorphism
results in abnormal lipid accumulation in skeletal
muscle and liver and other indices of metabolic
dysfunction.
Methods: 40 healthy men with a mean age of
55 years were characterized metabolically including
assessment of insulin sensitivity by the
hyperinsulinemic euglycemic clamp, intrahepatic lipid
content (IHLC) and intramyocellular lipid content
(IMCL) by MR spectroscopy, and β-cell function by an
intravenous glucose tolerance test. Changes in insulin
signaling and CD300LG mRNA expression were
determined by western blotting and quantitative PCR in
muscle and adipose tissue.
Results: Compared with the 20 controls (CC carriers),
the 20 CT carriers (polymorphism carriers) had higher
IMCL (p=0.045), a reduced fasting forearm glucose
uptake (p=0.011), a trend toward lower M-values
during the clamp; 6.0 mg/kg/min vs 7.1 (p=0.10), and
higher IHLC (p=0.10). CT carriers had lower CD300LG
mRNA expression and CD300LG expression in muscle
correlated with IMCL (β=−0.35, p=0.046), forearm
glucose uptake (β=0.37, p=0.03), and tended to
correlate with the M-value (β=0.33, p=0.06),
independently of CD300LG genotype. β-cell function
was unaffected.
Conclusions: The CD300LG polymorphism was
associated with decreased CD300LG mRNA expression
in muscle and adipose tissue, increased IMCL, and
abnormalities of glucose metabolism. CD300LG mRNA
levels correlated with IMCL and forearm glucose
uptake. These findings link a specific CD300LG
polymorphism with features of the metabolic syndrome
suggesting a role for CD300LG in the regulation of
common metabolic traits.
Trial registration number: NCT01571609.
BACKGROUND
The metabolic syndrome, comprising predia-
betes, abdominal obesity, hypertension, and
Key messages
▪ An amino acid polymorphism in CD300LG
(Arg82Cys), a protein which belongs to the
CD300 family of lipid-binding surface glycopro-
teins in highly vascularized tissues, has in
genetic-epidemiological studies been associated
with the fasting lipoprotein abnormalities of the
metabolic syndrome.
▪ We performed a comprehensive metabolic
phenotype characterization of healthy male car-
riers of the identical polymorphism to test the
hypothesis that the polymorphism may associate
with additional metabolic phenotypes.
▪ The CD300LG polymorphism was associated
with reduced expression of the gene in adipose
tissue and skeletal muscle, accumulation of lipid
in the skeletal muscle, and abnormalities in
glucose metabolism. The findings of the study
suggest a role for CD300LG in the regulation of
common metabolic phenotypes.
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dyslipidemia, is a risk factor for the future development
of type 2 diabetes (T2DM) and cardiovascular diseases
(CVD).1–3 Accumulation of lipids in muscle and liver is
associated with insulin resistance and is also a risk factor
for T2DM and CVD.4–6
Epidemiological studies have shown that prenatal and
postnatal environmental factors together with genetic
factors exert major inﬂuences on the risk of metabolic
disorders.7–15 Each of the aspects of the metabolic syn-
drome has been studied in large-scale genetic associ-
ation studies with a multitude of loci identiﬁed and
each associated with a subtle effect on disease suscepti-
bility.16–19 The hypothesis that metabolic disorders on
top of their phenotype-speciﬁc genes share overlapping
causative genes was addressed in a three-stage
genetic-epidemiological study combining whole exome
sequencing of 2000 Danish individuals with genotyping
and association studies in Danish and European indivi-
duals.20 A low-frequent amino acid polymorphism in
CD300LG (c.313 C>T, p.Arg82Cys) with a minor allele
frequency of 3.5% was associated with a decreased
fasting serum high-density lipoprotein (HDL) choles-
terol level and an increased fasting serum triglyceride
level, that is, components of the metabolic syndrome.
The protein encoded by CD300LG belongs to the
CD300 family of membrane-bound molecules, which
have broad and diverse immunological actions, includ-
ing the ability to recognize and interact with extracellu-
lar lipids.21 22 The CD300LG protein is expressed in a
broad range of tissues with highest expression in the
placenta, adipose tissue, and skeletal muscle.20 23 The
biological functions of CD300LG are not well character-
ized, but the protein has been implicated in lympho-
cyte interaction with endothelial cells in lymph node
capillaries,24 endocytosis of immunoglobulins,23 and
binding of polar lipids.22 The biological functions of
CD300LG in adipose tissue and skeletal muscle are
largely unknown, but with the present study we
propose a role for CD300LG in lipid storage in skeletal
muscle. It remains a distinct possibility that a genetic-
ally determined dysfunction of the CD300LG protein
could induce abnormal lipid deposition in insulin-
sensitive tissues, such as skeletal muscle contributing to
insulin resistance. On the basis of these considerations,
we performed a comprehensive metabolic phenotype
characterization of male carriers of CD300LG
rs72836561.
Our overall aim was to test if there are associations
between the Arg82Cys polymorphism in CD300LG and
metabolic phenotypes on whole body and tissue levels.
More speciﬁcally, we aimed at testing whether CD300LG
polymorphism carriers display reduced CD300LG
mRNA expression in insulin-sensitive target tissues
(muscle and fat) and whether any such genetic defects
translate into excessive lipid accumulation in muscle
and liver, features of insulin resistance, and metabolic
dysfunction in a homogeneous group of male
participants.
METHODS
Study participants were recruited from a Danish biobank
of nearly 10 000 participants.20 Members of the biobank
had been genotyped for the CD300LG polymorphism as
part of the genetic-epidemiological study.20 25 Potential
participants were invited to participate in the study
according to CD300LG genotype. Sixty male CD300LG
CT carriers (polymorphism carriers) fulﬁlled inclusion
criteria of age between 18 and 70 years, body mass index
(BMI) <30 kg/m2, and normal glucose tolerance and
were invited by letter to participate in the study; 20 CT
carriers were included in the study, 31 did not respond
to the invitation or did not wish to participate, and 9
had a medical condition that was incompatible with
study participation. High-performance athletes were not
included in the study (marathon runners, etc).
The 20 CD300LG CT carriers were age-matched and
BMI-matched with 20 healthy male CC carriers (con-
trols). The participants were examined over 2 days with
the aim of assessing the effects of the CD300LG poly-
morphism on metabolic, cardiovascular, and bone
health.25 Only data on metabolic health are included in
the present manuscript. Only men were included in the
study to avoid the effect of the menstrual cycle in
women on metabolic variables. The study participants
were healthy as assessed by medical history, a physical
examination, and a routine biochemical proﬁle.
All participants provided written informed consent.
The study protocol was approved by the Ethical
Committee of Region Midt (protocol number
1-10-72-113-12) and the studies were conducted accord-
ing to the principles of the Helsinki declaration. The
study was registered at clinicaltrials.gov (trial number
NCT01571609).
Design
After an overnight fast, the examination day started with
a whole body DXA scan for evaluation of body compos-
ition (Hologic QDR 2000). This was followed by a 2 h
basal period with infusion of a glucose and palmitate
tracer to assess the rate of endogenous glucose produc-
tion and free fatty acid (FFA) production. Ninety
minutes into the basal period, blood was sampled for a
biochemical proﬁle. The basal period was followed by a
Botnia clamp26 which combines an intravenous glucose
tolerance test (IVGTT; 60 min) with a hyperinsulinemic
euglycemic clamp (HEC; for 120 min). Indirect calorim-
etry was performed during the last 30 min of the basal
period and the clamp for assessment of resting energy
expenditure (REE) and respiratory quotient (RQ)
(Deltatrac monitor, Datex, Helsinki, Finland). Lipid and
glucose oxidation was estimated after correction for
protein oxidation, which was calculated from the urinary
urea excretion during the study day. Muscle and sub-
cutaneous adipose tissue (SAT) biopsies were collected
15 min into the basal period and repeated 50 min into
the clamp (ﬁgure 1). MR spectroscopy of the liver for
estimation of the intrahepatic lipid content (IHLC) and
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of the left anterior tibial muscle for estimation of the
intramyocellular lipid content (IMCL) was completed
on the morning of a separate day. IHLC and IMCL are
expressed as the arbitrary ratio between the lipid and
water signal in the voxel. Study participants were non-
fasting on the day of the MR spectroscopy. Study partici-
pants had refrained from major physical exercise for
48 h prior to both study days. The study participants
arrived by transportation to the research facilities on the
morning of the examination days.
Intravenous catheters
A catheter was inserted retrogradely in a deep antecubi-
tal vein for sampling of venous blood from the forearm.
Prior to sampling, a wrist cuff was inﬂated to suprasysto-
lic blood pressure to ensure that only blood from the
deep veins of the forearm was sampled. Regional blood
blow was estimated by venous occlusion plethysmogra-
phy. On the contralateral arm, an intravenous catheter
was inserted in a heated superﬁcial dorsal hand vein for
sampling of arterialized venous blood and in an antecu-
bital vein for infusions.27
Muscle and adipose tissue biopsies
Muscle tissue was obtained from the lateral vastus
muscle 15 cm proximal to the knee joint line by the use
of a Bergstrom biopsy needle. SAT was obtained from
the periumbilical region by liposuction with a 50 mL
syringe. Tissue samples were cleaned from visible blood
with sterile RNA-free saline, snap frozen in liquid nitro-
gen, and stored at −80°C.
Quantitative PCR
Real-time PCR assays were performed in duplicate for
assessment of CD300LG mRNA tissue expression in skel-
etal muscle and SAT and included no-template controls,
a calibrator sample, and a standard curve of ﬁve serial
dilution points of the calibrator sample based on a pool
of the sampled cDNAs. Relative expressions were calcu-
lated from standard curves using software implemented
in the light cycler. Target genes were normalized to
endogenous controls, and expressions relative to the
calibrator were calculated. For muscle tissue, cyclophilin
A (CP) and β-actin were used as internal reference
genes, whereas only CP was used in SAT. Further details
on the RNA isolation and PCR are provided in the
online supplementary material.
Western blotting
Skeletal muscle biopsies obtained under basal condi-
tions and during the clamp were used for western blot-
ting for assessment of dynamic changes in insulin
signaling downstream of the insulin receptor.
Quantiﬁcations of protein phosphorylation are
expressed as a ratio of phosphorylated protein to total
protein measured on the same membrane for
pAKT-threonine308/AKT2. For the ratios of pAS160/
AS160, pAKT-serine473/AKT2, pmTOR/mTOR, and
pGS/GS, the phosphorylated target and the total target
were measured on separate membranes and the ratios
were calculated after normalization for total protein of
the membranes. Detailed descriptions of the applied
methods are provided in the online supplementary
material.
Tracers
For the assessment of endogenous glucose production
(EGP) during the basal period, a 3-3H-glucose tracer
(New England Nuclear Life Science Products, Boston,
Massachusetts, USA) was infused for 120 min (0.15 µCi/
min). A priming dose 3-3H-glucose (15 µCi) was given as
a bolus prior to the constant infusion. Glucose rate of
appearance (Ra) was calculated from Steele’s equation
for non-steady state.28–30 For evaluation of endogenous
palmitate production during the basal period,
9.10-3H-palmitate was infused for 60 min (0.3 µCi/min)
Figure 1 Schematic overview of
the examination day. The MR
spectroscopy was performed on a
separate day (IVGTT, intravenous
glucose tolerance test).
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from time 60 to 120. Blood was sampled for measure-
ment of palmitate concentration and speciﬁc activity
(SA) at time 0, and at time 100, 110, and 120 for
steady-state analyses. Palmitate concentration and SA
were analyzed by high performance liquid chromatog-
raphy using 2H31-palmitate as an internal standard.
31
Systemic palmitate ﬂux (µmol/min) was calculated
using the 9.10-3H-palmitate infusion rate (dpm/min)
divided by the steady-state palmitate SA (dpm/µmol).32
Regional palmitate balances were estimated using blood
ﬂow, SA, and palmitate concentrations from arterial and
venous samples and calculated as previously described.33
IVGTT and HEC
The Botnia clamp model was used to assess β-cell func-
tion and insulin sensitivity on the same study day.26
A bolus of 25 g glucose from a 50% glucose solution was
given at time 120 min followed by blood sampling at
time 120, 122, 124, 126, 128, 130 for estimation of ﬁrst-
phase insulin release (FPIR) and C-peptide concentra-
tions. Blood was sampled at time 140, 160, and 180 min
for assessment of second-phase insulin release (SPIR)
and C-peptide concentrations. FPIR was quantiﬁed as
the time 120–130 and SPIR as the time 130–180 incre-
mental area under the curve (iAUC) insulin concentra-
tion.26 The clamp was started at time 180 with an insulin
infusion rate of 1 mU/kg/min (Insulin Actrapid,
Novo-Nordisk, Copenhagen, Denmark) until time 300.
Plasma glucose was clamped at 5 mmol/L by adjusting
an intravenous infusion of 20% glucose (200 g/L, SAD,
Copenhagen, Denmark) according to plasma glucose
measurements every 10 min (Beckmann Instruments,
Palo Alto, California, USA). Steady-state serum insulin
concentrations were measured at time 280, 290, and
300 min during the clamp. Insulin sensitivity in the two
genotype groups was calculated as the mean glucose
infusion rates (mg/kg/min) during the last 30 min of
the clamp, the M-value.34
MR spectroscopy
1H-MR spectroscopy was used to assess IHLC and IMCL
using a Signa Excite 1.5 Tesla Twin Speed scanner (GE
Medical systems, Milwaukee, Wisconsin, USA). The MR
spectroscopy of the liver and muscle included point
resolved spectroscopy sequences as described earlier.35
Spectrum quality was checked by visual inspection
during each examination and the mean full width at
half maximum was 10.0 (95% CI 9.5 to 10.5) Hz for
liver spectra and 10.8 (95% CI 10.0 to 11.6) Hz for
muscle spectra. Data processing provided an estimate of
the lipid-to-water ratio in the voxel (LC Model, Dr
Steven Provencher, Ontario, Canada).36 Three CT car-
riers were excluded from the analysis of IHLC due to
technical difﬁculties with the liver spectroscopy.
Assays
Plasma lipoproteins and procalcitonin were analyzed in
the Department of Clinical Biochemistry, Aarhus
University Hospital. Proinsulin (intact proinsulin kit,
Dakocytomation, Glostrup, Denmark), insulin (DAKO,
Glostrup, Denmark), C-peptide (ALPCO, Salem, New
Hampshire, USA), and cortisol (EIA-1887,
AH-Diagnostic) were analyzed using ELISA-based kits.
FFAs were analyzed with a commercial kit (Wako chemi-
cals, Neuss, Germany). High-sensitive C reactive protein
(BAM 17072 and MAB 17071, R&D Systems Europe Ltd,
Abingdon, UK) and osteoprotegerin (OPG/
TNFRSF11B, R&D Systems Europe Ltd, Abingdon, UK)
were analyzed using an in-house ELISA assay.
Adiponectin was analyzed using a commercial time-
resolved immunoﬂuorometric assay (TR-IFMAs;
Autodelﬁa, PerkinElmer, Turku, Finland). Glucagon was
analyzed by an in-house radioimmunoassay.37 Plasma
mannose-binding lectin was determined by a TR-IFMA
as previously described.38 Blood for analyses of proinsu-
lin was sampled at time 90 min (basal period) and for
glucagon at time 100, 110, 120, 180, 280, 290, and 300.
Statistical analysis
Statistical analyses were performed using SPSS V.21.0.
Results are presented as mean±95% CI or median±IQR.
A Student t test was applied to compare the two geno-
type groups. Non-parametric data were log-transformed
to obtain normality. For data that did not achieve
normal distribution on log-transformation, between-
group comparisons were performed using a
Wilcoxon-Mann-Whitney U test. p-values <0.05 were con-
sidered signiﬁcant. A multiple regression model was
applied to adjust the M-value for steady-state serum
insulin concentration (clamp). The analyses of FPIR and
SPIR included adjustment for the M-value. Linear
regression with the log-transformed CD300LG mRNA
level as the independent variable was used to test for cor-
relation with relevant outcome measures. A Fisher’s
exact test was used to test for association between dichot-
omous variables. A mixed analysis of variance with
repeated measurements was used for analysis of data
available for both the basal period and the clamp. The
between-participant factor was genotype and the within-
participant factor was condition (fasting or insulin-
stimulated). The within-participant effect of insulin
stimulation was evaluated by a paired t test. Main out-
comes were also adjusted for mean arterial pressure.
Power calculations were based on the glucose infusion
rates during the clamp, and with 20 study participants in
each genotype group, the statistical power to detect a
20% difference in glucose infusion rates during the
clamp was >80%. Box plots were generated using a web
tool for generation of box plots (http://boxplot.
tyerslab.com/).39
RESULTS
Anthropometrics
Clinical characteristics of the study participants are pre-
sented in table 1.
4 BMJ Open Diabetes Research and Care 2015;3:e000095. doi:10.1136/bmjdrc-2015-000095
Metabolism
group.bmj.com on December 29, 2017 - Published by http://drc.bmj.com/Downloaded from 
Substrate metabolism and insulin sensitivity
Forearm metabolism was evaluated in the basal period
by assessing arteriovenous differences of glucose and
FFA. Fasting EGP and palmitate kinetics were evaluated
using a 3-3H-glucose tracer and a 9.10-3H-palmitate
tracer, respectively (table 2). The glucose uptake in the
forearm was reduced in CT carriers under basal condi-
tions, but no differences were detected between groups
in rates of EGP or in palmitate kinetics.
Insulin sensitivity was assessed by use of an HEC.
Arteriovenous substance differences were also evaluated
during insulin stimulation. A trend toward lower insulin
sensitivity in CT carriers was detected; the M-value in the
CT group was 5.96 mg/kg/min (95% CI 4.99 to 6.93)
compared with 7.07 (6.08 to 8.05) in the CC group
(p=0.10; ﬁgure 2). Steady-state insulin concentrations
during the clamp was 404 pmol/L (95% CI 358 to 450)
in CT carriers compared with 418 (391 to 444) in CC
carriers (p=0.58). Adjusting the M-value for serum
insulin concentration during the steady state of the
clamp had some effect on the results (p=0.08). There
was no effect of genotype on arteriovenous balances of
glucose or FFA during the HEC. There were no
between-group differences in forearm blood ﬂow during
the basal period or during the clamp (data not shown).
β-cell function
β-cell function was assessed by FPIR and SPIR in
response to intravenous administration of 25 g glucose
(ﬁgure 3). There were no genotype-group differences in
the iAUC of glucose, insulin, or C-peptide from time
120–130 (glucose, p=0.97; FPIR, p=0.37; C-peptide,
p=0.18) or time 130–180 (glucose, p=0.93; SPIR, p=0.20;
C-peptide, p=0.28). Adjusting the data for the M-value
did not change the results.
Energy expenditure
Fasting and insulin-stimulated REE and RQ were
obtained by indirect calorimetry. The genotype of the
study participants did not affect basal and insulin-
stimulated energy expenditure and substrate oxidation
(table 2).
MR spectroscopy
IMCL was 0.005 au (95% CI 0.0038 to 0.0062) in the CT
carriers compared with 0.004 in the controls (0.0029 to
0.0044), p=0.045. The median IHLC in CT -carriers was
0.07 (IQR 0.036–0.18) compared with 0.043 (0.024–
0.068) in the controls (p=0.10; ﬁgure 4A, B).
Table 1 Anthropometric data on the 40 male study participants according to CD300LG rs72836561 CC and CT genotype
Variable CC (n=20) CT (n=20) p-Value
Anthropometry
Age (years) 55.1 (50.8 to 59.2) 55.0 (50.8 to 59.3) 0.99
BMI (kg/m2) 24.6 (23.8 to 25.5) 24.5 (23.4 to 25.6) 0.79
Systolic blood pressure (mm Hg) 130 (126 to 133) 140 (132 to 147) 0.02
Diastolic blood pressure (mm Hg) 78 (75 to 82) 84 (81 to 87) 0.02
Waist circumference (cm) 91.9 (88.5 to 95.4) 92.5 (89.0 to 95.9) 0.82
Current smokers (yes/no) 1/19 5/15 0.18
Body composition from DXA scan
Lean body mass (kg) 59.0 (56.7 to 61.3) 58.3 (55.3 to 61.4) 0.72
Fat mass (kg) 16.9 (15.1 to 18.6) 16.9 (15.0 to 18.8) 0.99
Fat per cent (%) 21.4 (19.6 to 23.2) 21.5 (19.9 to 23.1) 0.90
Fasting blood samples
HbA1c (IFCC, mmol/mol) 35.2 (33.8 to 36.5) 35.7 (34.5 to 36.9) 0.56
HbA1c (%) 5.4 (5.2 to 5.5) 5.4 (5.3 to 5.5) 0.65
Glucose (mmol/L) 5.4 (5.3 to 5.6) 5.5 (5.2 to 5.7) 0.81
Total cholesterol (mmol/L) 5.3 (5.0 to 5.6) 5.1 (4.7 to 5.4) 0.18
LDL (mmol/L) 3.4 (3.1 to 3.7) 3.1 (2.8 to 3.4) 0.19
HDL (mmol/L)* 1.4 (1.1 to 1.7) 1.2 (1.0 to 1.5) 0.42
Triglyceride (mmol/L)* 1.1 (0.8 to 1.4) 1.3 (0.7 to 1.7) 0.49
Insulin (pmol/L)* 34.7 (24.5 to 50.0) 39.7 (26.8 to 54.0) 0.61
Proinsulin (pmol/L)* 3.41 (2.71 to 4.80) 4.00 (2.73 to 5.44) 0.26
Proinsulin/insulin ratio 0.12 (0.09 to 0.15) 0.13 (0.10 to 0.15) 0.67
C-peptide (pmol/L)* 362 (283 to 384) 375 (292 to 544) 0.22
Proinsulin/C-peptide 0.011 (0.009 to 0.013) 0.012 (0.009 to 0.014) 0.78
HOMA-B (%) 55.3 (44.7 to 65.9) 61.8 (47.4 to 76.1) 0.45
HOMA-IR 1.27 (1.03 to 1.52) 1.55 (1.07 to 1.99) 0.28
Mean and 95% CI.
*Median and IQR.
BMI, body mass index; CC, control; CT, polymorphism carriers; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; IFCC,
international federation of clinical chemistry; LDL, low-density lipoprotein.
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Table 2 Various measures of insulin sensitivity and energy expenditure in the 40 male study participants according to CD300LG rs72836561 CC and CT genotype
CC (n=20) CT (n=20)
p-valueBasal Clamp Basal Clamp
Indirect calorimetry
Respiratory quotient 0.81 (0.79 to 0.83) 0.92 (0.90 to 0.94) 0.82 (0.80 to 0.84) 0.92 (0.90 to 0.94) <0.01*/0.24†/0.39‡
Energy expenditure (kcal/24 h) 1617 (1555 to 1679) 1713 (1650 to 1776) 1675 (1581 to 1769) 1721 (1637 to 1804) <0.01*/0.29†/0.12‡
Glucose oxidation (mg/kg/min) 1.03 (0.75 to 1.32) 2.46 (2.15 to 2.79) 1.28 (0.98 to 1.59) 2.46 (2.16 to 2.76) <0.01*/0.49†/0.32‡
Protein oxidation (mg/kg/min) 0.49 (0.39 to 0.59) 0.45 (0.35 to 0.56) 0.55 (0.40 to 0.70) 0.65 (0.52 to 0.79) 0.65*/0.56†/0.11‡
Lipid oxidation (mg/kg/min) 0.81 (0.69 to 0.93) 0.33 (0.22 to 0.44) 0.76 (0.61 to 0.91) 0.26 (0.16 to 0.37) <0.01*/0.20†/0.77‡
Forearm glucose uptake (mmol/100 mL/min)/103 0.27 (0.18 to 0.36) 2.43 (1.75 to 3.12) 0.11 (0.02 to 0.20) 2.37 (1.38 to 3.35) <0.01*/0.01†/0.86‡
FFA (mmol/L)
FFA, arterial 1.07 (0.90 to 1.25) 0.06 (0.04 to 0.07) 0.96 (0.82 to 1.1) 0.07 (0.05 to 0.08) <0.01*/0.32†/0.29‡
FFA, venous 1.07 (0.93 to 1.21) 0.06 (0.04 to 0.07) 0.95 (0.77 to 1.13) 0.07 (0.05 to 0.09) <0.01*/0.39†/0.33‡
Endogenous glucose production (mg/kg/min) 1.72 (1.35 to 1.84) – 1.62 (1.43 to 2.05) – 0.94†
Palmitate flux (µmol/min) 173 (145 to 201) – 182 (151 to 213) – 0.80†
Forearm palmitate kinetics (µmol/100 mL/min)
Palmitate uptake 0.080 (0.063 to 0.098) – 0.073 (0.058 to 0.088) – 0.53†
Palmitate net release 0.0006 (−0.024 to 0.015) – −0.011 (−0.028 to 0.005) – 0.53†
Palmitate release 0.0734 (0.053 to 0.108) – 0.057 (0.034 to 0.112) – 0.20†
Miscellaneous
Glucagon (pg/mL) 48.9 (40.7 to 57.1) 35.0 (27.0) 49.5 (41.9 to 57.0) 34.8 (29.2 to 40.4) <0.01*/0.84†/0.83‡
Adiponectin (mg/L) 9.5 (7.7 to 11.3) 8.5 (6.9 to 10.0) 0.37†
Procalcitonin (μg/L) 0.04 (0.02 to 0.04) 0.04 (0.02 to 0.04) 0.95¶
Osteoprotegrin (pg/mL) 669 (550 to 948) 758 (566 to 878) 0.75§
Cortisol (ng/mL) 66 (52 to 91) 66 (52 to 85) 0.71¶
HsCRP (mg/L) 1.35 (0.39 to 3.63) 1.24 (0.66 to 2.96) 0.91§
Mannan-binding lectin (nm/mL) 1084 (355 to 1400) 404 (161 to 1874) 0.59¶
Mean and 95% CI unless otherwise indicated.
*p-value from paired t test comparing basal to insulin-stimulated values.
†p-value from Student t test (comparison of mean basal values).
‡Mixed ANOVA where data are available from the basal period and from the clamp. The factors genotype and condition (basal/clamp) were included in the model. p-values represent interaction
between genotype and condition.
§Median and IQR. p-value from Student t test of log-transformed data.
¶Median and IQR. p-value from Wilcoxon-Mann-Whitney U test.
ANOVA, analysis of variance; CC, control; CT, polymorphism carriers; FFA, free fatty acid; HsCRP, high-sensitive C reactive protein.
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Gene expression
The relative expression of CD300LG mRNA was deter-
mined by real-time quantitative PCR of skeletal muscle
and SAT. The median relative expression of CD300LG
mRNA in skeletal muscle in CC carriers was 0.79 (IQR
0.68–1.34) compared with 0.54 (IQR 0.37–0.72) in the
CT carriers (p=0.006; ﬁgure 5A). Gene expression ana-
lysis in SAT was performed in a subset of study partici-
pants (when sufﬁcient SAT for mRNA extraction was
available (n=23); ﬁgure 5B). The median relative expres-
sion of CD300LG in SAT in the CC group was 0.72 (IQR
0.58–0.91) compared with 0.56 (IQR 0.34–0.60) in the
CT carriers (p=0.04). The reference genes, β-actin and
CP, had similar expression in both genotype groups
(data not shown). Independently of the genotype,
CD300LG expression in skeletal muscle correlated with
IMCL (β=−0.35, p=0.046), M-value (β=0.33, p=0.06), and
arteriovenous glucose differences (β=0.37, p=0.03).
There was no correlation between IHLC and CD300LG
mRNA expression (β=−0.22, p=0.21; see online
supplementary ﬁgure 1A–C).
Blood pressure
Ofﬁce blood pressure and 24 h ambulatory blood pres-
sure (data not shown) were higher in the CT group
than in the CC group. Blood pressure levels did not cor-
relate with forearm glucose uptake, IMCL, M-value, or
CD300LG mRNA expression in this study (data not
shown). There was only a marginal effect on the main
outcomes of adjusting for mean arterial pressure:
M-value (p=0.11), IMCL (p=0.045), fasting glucose
arteriovenous difference (p=0.005), and IHLC (p=0.16).
Western blots
Skeletal muscle biopsies obtained under basal condi-
tions and at 50 min into the HEC were used for western
blotting for assessment of dynamic changes in insulin
signaling downstream of the insulin receptor. Insulin
had a profound effect on the ratio between phosphory-
lated and total protein levels for AKT2, pAKT-serine473,
pAKT-threonine308, AS160, and pAS160-threonine642.
Insulin had a clear stimulatory effect on protein and
glycogen synthesis as suggested by the increasing
pmTOR/mTOR ratio from basal conditions to the
clamp and a decreasing pGS/GS in the same time inter-
val. The genotype of the study participants did not affect
signaling events in skeletal muscle (data not shown).
DISCUSSION
The protein encoded by CD300LG belongs to a family of
membrane-bound proteins which have the ability to rec-
ognize and interact with extracellular lipids,21 22 and in
a recent genetic-epidemiological study, the Arg82Cys
polymorphism was found to be associated with the lipo-
protein abnormalities of the metabolic syndrome, that
is, reduced fasting serum levels of HDL cholesterol and
elevated serum levels of triglyceride.20 Our study was
designed to test whether the CD300LG polymorphism is
associated with decreased mRNA expression in insulin-
sensitive tissues, altered intracellular lipid content, and
insulin resistance. Our key ﬁndings include lower expres-
sion of CD300LG mRNA in muscle and fat, higher
IMCL, a reduced basal forearm glucose uptake, and a
trend toward decreased insulin sensitivity in CT carriers.
Our data suggest a gene dosage effect with a signiﬁcant
correlation between CD300LG expression in skeletal
muscle and IMCL and fasting forearm glucose uptake.
We also observed a signiﬁcant increase in ofﬁce blood
pressure and 24 h ambulatory blood pressure in CT car-
riers, but we were not able to replicate this association in
a larger external cohort where CD300LG genotype and
ofﬁce blood pressure were available.25
The comprehensive protocol may be viewed as a
strength of our study. The protocol allowed for detailed
Figure 2 Box plot representing
the median GIRs (mg/kg/min) by
CD300LG genotype during the
last 30 min of the HEC. The
center lines show the medians;
box limits indicate the 25th and
75th centiles; whiskers extend 1.5
times the IQR from the 25th and
75th centiles. CC, control; CT,
polymorphism carriers; GIR,
glucose infusion rate; HEC,
hyperinsulinemic euglycemic
clamp.
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insights into dynamic measures of glucose and lipid
turnover on whole body and tissue level and provided
in-depth characterization of the metabolic phenotypes
of the study participants. In the genetic-epidemiological
gene discovery study, despite using a large study cohort,
no signal was detected for additional metabolic traits or
phenotypes for the CD300LG polymorphism (other than
the observed changes in the lipoprotein proﬁle).20
Furthermore, the study participants in this study were
heterogeneous with respect to gender and metabolic
health, and associations between the CD300LG poly-
morphism and metabolic traits and phenotypes were
tested on fasting levels of glucose and insulin, or using
dichotomized data with study participants grouped into
diabetic/non-diabetic. Potentially, the effects of the poly-
morphism on dynamic measures of glucose and lipid
metabolism (or on unmeasured variables such as IMCL)
could have been missed in the large-scale study. In the
present study we aimed at detecting novel associations
between the CD300LG polymorphism and metabolic
phenotypes through a detailed phenotype characteriza-
tion of the study participants.
The CT polymorphism induced a signiﬁcant reduction
in CD300LG mRNA expression in adipose tissue and
muscle. In SAT, large amounts of tissue were required to
extract sufﬁcient mRNA for cDNA synthesis reducing the
number of participants available for the analyses. Owing
to low yields of RNA from SAT, we were unable to inspect
the integrity of the RNA on an agarose gel. On the other
hand, yields of mRNA from muscle tissue were high and
we were able to evaluate RNA integrity. Consequently,
gene expression data from skeletal muscle seem solid,
whereas the ﬁndings in AT should be interpreted more
cautiously. Whether the reduced CD300LG mRNA
Figure 3 (A–B) Plasma glucose
concentration (mmol/L) by
CD300LG genotype during the
IVGTT (time 120–180) and during
the HEC (time 180–300) (A) and
FPIR and SPIR (pmol/L) by
CD300LG genotype during the
IVGTT (time 120–180) and insulin
concentrations during the HEC
(time 180–300) (B). The CT group
is represented by black triangles
and the CC group is represented
by black circles. The whiskers
correspond to 95% CI. AUC, area
under the curve; CC, control; CT,
polymorphism carriers; FPIR,
first-phase insulin release; HEC,
hyperinsulinemic euglycemic
clamp; SPIR, second-phase
insulin release.
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expression in skeletal muscle and adipose tissue in poly-
morphism carriers translates into quantitative and/or
structural changes in the CD300LG protein is currently
unknown. Future studies of the impact of the CD300LG
polymorphism on human metabolism could include
studies of the effect of the polymorphism on CD300LG
protein expression and structure.
Our data show that CT carriers had a higher IMCL and
tended to have higher IHLC than controls as evaluated by
MR spectroscopy. A considerable body of evidence sug-
gests that excessive accumulation of lipids in muscle and
liver in sedentary persons is associated with insulin resist-
ance,4–6 possibly mediated by speciﬁc intracellular lipid
fractions such as diacylglycerol (DAG) and ceramide.40 It
has been shown that in obesity, increased IMLC is asso-
ciated with increased intracellular DAG and ceramide con-
tents.41 42 However, the cause and effect relationship of
these associations remains to be ﬁnally established. Our
data support and expand the concept of IMCL-associated
insulin resistance by providing evidence that in humans a
speciﬁc polymorphism in CD300LG leads to the combin-
ation of high IMCL and indices of abnormal glucose turn-
over. The biological roles of the CD300 group of
transmembrane molecules are not well characterized, but
it appears that the CD300 receptors exist in activating and
inhibitory forms, which engage in speciﬁc interactions
with major polar lipids of cell membranes;21 22 whether
and, if so, how CD300LG is involved in lipid turnover in
skeletal muscle cells remains elusive. Furthermore, the
effect of dysfunction or reduced amounts of the CD300LG
protein in polymorphism carriers on this proposed func-
tional relationship is unknown, but it may include intracel-
lular lipid accumulation and insulin resistance as
suggested by results from this study.
Figure 4 (A–B) Box plot
representing the median IMCL (A)
and IHLC (B) as assessed by MR
spectroscopy by CD300LG
genotype. Other definitions of the
plot are described in the legend
to figure 2. CC, control; CT,
polymorphism carriers; IHCL,
intrahepatic lipid content; IMCL,
intramyocellular lipid content.
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Although we only saw a tendency towards lower M-
values during the HEC in CT-carriers, we observed a
lower fasting glucose uptake in the forearm when com-
pared with the controls and skeletal muscle CD300LG
mRNA expression correlated well with IMCL, M-value,
and forearm glucose uptake when all participants were
assessed as a whole. Taken together, these ﬁndings
strongly suggest the existence of insulin resistance,
although the fasting glucose uptake is also determined
by insulin-independent mechanisms. We observed no
effect of CD300LG genotype on forearm glucose uptake
during the clamp, but a trend toward reduced insulin
sensitivity in CT carriers. A decreased suppression of
EGP during the clamp due to hepatic insulin resistance
could have affected the results, but in healthy partici-
pants the relatively high insulin dose (1 mU/kg/min)
has been shown to suppress the EGP by 98%.43
Unfortunately, EGP was only determined under fasting
conditions as the Botnia clamp model has not been
validated for simultaneous use of a glucose tracer.
Consequently, with the present data, we are unable to
assess the role of the liver in glucose turnover during
the clamp. In this context, it should be noticed that the
experimental procedures of the current investigation are
relatively demanding and complex, therefore only allow-
ing for a limited number of participants to be investi-
gated. In addition, many genetic and lifestyle-related
environmental factors may introduce biological noise
and affect the outcome in an investigation such as ours.
The effect of the CD300LG polymorphism on clinical
measures of insulin sensitivity did not translate into
changes that were detectable using western blot analysis
of signaling pathways downstream of the insulin receptor
in skeletal muscle. We did detect a clear dynamic
response to insulin when comparing basal conditions
with insulin-stimulated conditions, but this response did
not differ between genotype groups. We obtained a
broad biochemical proﬁle to explore the mechanisms
Figure 5 (A–B) Box plot
representing the median relative
expression of CD300LG mRNA in
skeletal muscle (A) and in SAT
(B) by CD300LG genotype. Other
definitions of the plot are
described in the legend to
figure 2. CC, control; CT,
polymorphism carriers; SAT,
subcutaneous adipose tissue.
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underlying the metabolic changes in CD300LG CT car-
riers. No differences between genotype groups were
detected for the measured endocrine hormones and
inﬂammatory markers.
For practical purposes, we used the Botnia clamp
model which combines measures of β-cell function and
insulin sensitivity on a single study day.26 Whereas the
glucose clamp offers a sensitive and reproducible way of
evaluating insulin sensitivity, the IVGTT may be less
accurate for determining β-cell function.44 We are not
aware of any data linking the CD300LG polymorphism to
β-cell function, and we did not detect any effects of
CD300LG on any measures of insulin secretion.
As mentioned, the relatively low number of study parti-
cipants was a limitation to our study as it may reduce the
statistical power to draw solid conclusions. The ﬁnding of
a correlation between CD300LG expression and mea-
sures of insulin sensitivity despite the low number of par-
ticipants therefore suggests the existence of a relatively
robust signal and indicates that the ﬁndings are not
merely reﬂecting a type 1 error. With the low frequency
of the CD300LG polymorphism, it required a large
biobank of 10 000 participants to include 20 suitable
male CT carriers in the study. We did not include women
in the study due to the use of radioactive tracers and the
impact of menstrual cycle on metabolic measurements.
It would, however, be of interest to include women in a
future CD300LG phenotype study as the effects on lipid
traits were more pronounced in women in the original
genetic-epidemiological study.20
Although the effect of the CD300LG polymorphism on
the fasting serum HDL cholesterol and triglyceride level
was discrete in the genetic-epidemiological study,20 the
effect of the polymorphism on fasting serum HDL chol-
esterol was marked when compared with previously
genome wide association study (GWAS)-identiﬁed HDL
cholesterol-associated variants.16 The association
between the CD300LG polymorphism and lipid traits was
detected using several thousand study participants, sug-
gesting that we were underpowered to detect a signiﬁ-
cant effect on fasting serum HDL cholesterol and
triglyceride levels in this study.
CONCLUSIONS
Our data point to an effect of the CD300LG rs72836561
polymorphism on IMCL, fasting forearm glucose
uptake, and on expression of CD300LG mRNA in SAT
and muscle. Independently of the genotype, CD300LG
mRNA expression was found to associate with IMCL and
measures of glucose turnover. Conclusively, our data link
a speciﬁc CD300LG polymorphism with features of the
metabolic syndrome suggesting a role for CD300LG in
the regulation of common metabolic traits.
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